Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Tielt-Winge – page 43

1 990 clinical trials in Tielt-Winge, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tielt-Winge at a glance
1 990
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 990 trials in Tielt-Winge

Open in trial search

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:EQUINE SHIGA TOXIN 1/2 IMMUNE FAB2
  • Sponsor:Chemo Research S.L.

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study on Preventing Hepatic Encephalopathy with Rifaximin and Lactulose in Patients with Alcoholic Liver Cirrhosis Undergoing TIPS Placement

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Lactulose
  • Sponsor:Amsterdam UMC Stichting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate
  • Sponsor:Blueprint Medicines Corp.

Lymphoma+4

Recruiting

Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imsidolimab
  • Sponsor:OSE Immunotherapeutics

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Tielt-Winge

What the registry says about research in the country

01 Gastroenterology Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. Research explores innovative approaches to medication management, particularly in the context of proton pump inhibitor (PPI) usage.

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

This research evaluates various therapeutic alternatives including on-demand medication use and alginate-based treatments, aiming to improve patient care in chronic digestive conditions.

02 Primary Care Innovation

Studies investigating optimal management of chronic acid-related disorders in primary care settings. Research examines patient-centered approaches to reducing long-term medication dependency.

  • Treatment Optimization
  • Patient-Centered Care
  • Medication Management

The research aims to establish evidence-based guidelines for managing common conditions like heartburn and reflux while minimizing unnecessary long-term medication use.

03 Therapeutic Alternatives

Investigation of comparative effectiveness between different treatment strategies for gastrointestinal disorders. Focus on developing sustainable approaches to managing chronic conditions.

  • Comparative Treatment Studies
  • Long-term Care Strategies
  • Clinical Effectiveness Research

Research evaluates the success rates of various therapeutic approaches, aiming to identify optimal strategies for long-term patient care and improved outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.